Jump to Main Content
Daily watermelon consumption decreases plasma sVCAM-1 levels in overweight and obese postmenopausal women
- Shanely, R. Andrew, Zwetsloot, Jennifer J., Jurrissen, Thomas J., Hannan, Lauren C., Zwetsloot, Kevin A., Needle, Alan R., Bishop, Anna E., Wu, Guoyao, Perkins-Veazie, Penelope
- Nutrition research 2020 v.76 pp. 9-19
- arginine, atherogenesis, atherosclerosis, blood glucose, body fat, fasting, fruit puree, glycemic control, insulin, insulin resistance, overweight, postmenopause, watermelons, women
- Postmenopausal status is associated with an increase in total and abdominal body fat as well as increased incidence of insulin resistance and cardiovascular disease. The purpose of this study was to determine if watermelon supplementation affects select systemic markers of atherosclerosis and measures of insulin resistance in overweight and obese postmenopausal women. We hypothesized that overweight and obese postmenopausal women consuming 100% watermelon puree daily for 6 weeks would have improved levels of select systemic markers connected with cardiovascular disease without changing markers of insulin resistance. To test this hypothesis, overweight and obese postmenopausal women were recruited to participate in this study. Participants were randomly assigned to either the control group (no intervention) or the watermelon puree group (WM) for 6 weeks. Plasma concentration of markers connected with atherosclerosis and glycemic control were measured pre- and poststudy. A significant 6% decrease in soluble vascular cell adhesion molecule-1 occurred pre- to poststudy in WM, P = .003. The pattern of change in fasting blood glucose (P = .633), insulin (P = .158), and homeostatic model assessment–estimated insulin resistance (P = .174) did not differ between groups. Pre- to poststudy increases were measured in the fasting plasma concentration of l-arginine (8%, P = .005), cis-lycopene (32%, P = .003), and trans-lycopene (42%, P = .003) in WM. We conclude that 6 weeks of watermelon supplementation improved soluble vascular cell adhesion molecule-1 levels, a marker connected to atherogenesis, independent of changes in body composition or glycemic control.